{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:53Z","timestamp":1792714253946,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016204","name":"Minnesota Supercomputing Institute, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI136982"],"award-info":[{"award-number":["R01AI136982"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.apsb.2021.08.019","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T15:55:27Z","timestamp":1629734127000},"page":"1671-1684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus (HCMV)"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-5970","authenticated-orcid":false,"given":"Sameera","family":"Senaweera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-2671","authenticated-orcid":false,"given":"Tiffany C.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakanth","family":"Kankanala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-7312","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-4684","authenticated-orcid":false,"given":"Rajkumar Lalji","family":"Sahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-5203","authenticated-orcid":false,"given":"Jiashu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-6509","authenticated-orcid":false,"given":"Robert J.","family":"Geraghty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5986","authenticated-orcid":false,"given":"Zhengqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.08.019_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.apsb.2021.08.019_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/microorganisms8050685","article-title":"Where do we stand after decades of studying human cytomegalovirus?","volume":"8","author":"Gugliesi","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2021.08.019_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (cmv) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.apsb.2021.08.019_bib4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12879-019-4643-6","article-title":"Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy","volume":"19","author":"Perello","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.apsb.2021.08.019_bib5","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.08.019_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","article-title":"New therapies for human cytomegalovirus infections","volume":"159","author":"Britt","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2021.08.019_bib7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.08.019_bib8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.apsb.2021.08.019_bib9","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2021.08.019_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.apsb.2021.08.019_bib11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/187152611797636668","article-title":"The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis","volume":"11","author":"James","year":"2011","journal-title":"Infect Disord - Drug Targets"},{"key":"10.1016\/j.apsb.2021.08.019_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.apsb.2021.08.019_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2021.08.019_bib14","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2021.08.019_bib15","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.001","article-title":"In\u00a0vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation","volume":"11","author":"Frietsch","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.apsb.2021.08.019_bib16","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in\u00a0vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2021.08.019_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","article-title":"Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections","volume":"161","author":"Gentry","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2021.08.019_bib18","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMe1401567","article-title":"Taming the transplantation troll by targeting terminase","volume":"370","author":"Griffiths","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.08.019_bib19","article-title":"Inhibition of human cytomegalovirus pul89 terminase subunit blocks virus replication and genome cleavage","volume":"91","author":"Wang","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2021.08.019_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2018.01.015","article-title":"Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication","volume":"152","author":"Wang","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2021.08.019_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cmdc.201800283","article-title":"Hydroxypyridonecarboxylic acids as inhibitors of human cytomegalovirus pUL89 endonuclease","volume":"13","author":"Kankanala","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2021.08.019_bib22","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1093\/nar\/gkt1414","article-title":"The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification","volume":"42","author":"Majorek","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2021.08.019_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/embor.2008.256","article-title":"Retroviral integrase superfamily: the structural perspective","volume":"10","author":"Nowotny","year":"2009","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2021.08.019_bib24","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1021\/acsomega.8b01472","article-title":"Structure-driven discovery of alpha,gamma-diketoacid inhibitors against UL89 herpesvirus terminase","volume":"3","author":"Bongarzone","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.apsb.2021.08.019_bib25","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1021\/acs.jmedchem.6b00465","article-title":"Design, synthesis, and biological evaluations of hydroxypyridonecarboxylic acids as inhibitors of HIV reverse transcriptase associated RNase H","volume":"59","author":"Kankanala","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.08.019_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in\u00a0vitro by a novel series of TIBO derivatives","volume":"343","author":"Pauwels","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.08.019_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nprot.2011.330","article-title":"A time-of-drug addition approach to target identification of antiviral compounds","volume":"6","author":"Daelemans","year":"2011","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2021.08.019_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1461-5347(98)00097-2","article-title":"Physical chemical properties of oral drug candidates in the discovery and exploratory development settings","volume":"1","author":"Curatolo","year":"1998","journal-title":"Pharmaceut Sci Technol Today"},{"key":"10.1016\/j.apsb.2021.08.019_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2021.08.019_bib30","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1128\/JVI.79.12.7792-7802.2005","article-title":"Interaction between the human cytomegalovirus UL82 gene product (pp71) and hdaxx regulates immediate-early gene expression and viral replication","volume":"79","author":"Cantrell","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2021.08.019_bib31","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/viro.1993.1192","article-title":"Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate","volume":"193","author":"Compton","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.apsb.2021.08.019_bib32","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11095-007-9517-8","article-title":"A novel design of artificial membrane for improving the pampa model","volume":"25","author":"Chen","year":"2008","journal-title":"Pharm Res-Dordr"},{"key":"10.1016\/j.apsb.2021.08.019_bib33","series-title":"Schr\u00f6dinger small-molecule drug discovery suite 2019-4","author":"Schr\u00f6dinger","year":"2019"},{"key":"10.1016\/j.apsb.2021.08.019_bib34","series-title":"Schr\u00f6dinger release 2019-4: Maestro","author":"Schr\u00f6dinger","year":"2019"},{"key":"10.1016\/j.apsb.2021.08.019_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.apsb.2021.08.019_bib36","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2021.08.019_bib37","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.08.019_bib38","series-title":"The pymol molecular graphics system","author":"Schr\u00f6dinger","year":"2019"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521003099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T20:41:21Z","timestamp":1749847281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521003099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2211383521003099"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.08.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus (HCMV)","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}